Future treatment of gonorrhoea – novel emerging drugs are essential and in progress?

Bibliography

• World Health Organization (WHO). Global incidence and prevalence of selected curable sexually transmitted infections - 2008. Geneva, Switzerland; 2012. Available from: http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf [8 February 2015]
   Google Scholar
• Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012;7:1401–22
   PubMed Web of Science ®Google Scholar
• Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: past, evolution, and future. Clin Microbiol Rev 2014;27:587–613
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Department of reproductive health and research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. WHO, Geneva; 2012. p. 1–36. Available from: http://www.who.int/reproductivehealth/publications/rtis/9789241503501 [8 February 2015]
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Cephalosporin-resistant Neisseria gonorrhoeae public health response plan. 2012. p. 1–43. Available from: http://www.cdc.gov/std/gonorrhea/default.htm [8 February 2015]
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe. ECDC, Stockholm; 2012. p. 1–23. Available from: http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf [8 February 2015]
   Google Scholar
• Bignell C, Unemo M; on behalf of the European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013;24:85–92
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61:590–4
   PubMedGoogle Scholar
• Ison CA, Deal C, Unemo M. Current and future treatment options for gonorrhoea. Sex Transm Infect 2013;89(Suppl 4):iv52–iv6
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Strategies and laboratory methods for strengthening surveillance of sexually transmitted infections. Available from: http://apps.who.int/iris/bitstream/10665/75729/1/9789241504478_eng.pdf [8 February 2015]
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Antibiotic-resistant strains of Neisseria gonorrhoeae: policy guidelines for detection, management and control. MMWR 1987;36(Suppl 5S):13S
   PubMedGoogle Scholar
• Roy K, Wang SA, Meltzer MI. Optimizing treatment of antimicrobial-resistant Neisseria gonorrhoeae. Emerg Infect Dis 2005;11:1265–73
   PubMed Web of Science ®Google Scholar
• Goire N, Lahra MM, Chen M, et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol 2014;12:223–9
   PubMed Web of Science ®Google Scholar
• Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014;59:1083–91
   PubMed Web of Science ®Google Scholar
• Hauser C, Hirzberger L, Unemo M, et al. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother 2015;59(3):1605–11
   PubMed Web of Science ®Google Scholar
• Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains including those with various high-level antimicrobial resistance - potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012;56:2739–42
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Golparian D, Phan LT, et al. In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother 2015;70:173–7
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Golparian D, Alm RA, et al. High in-vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 2014;58:5585–8
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Vu DM, Punjabi R, et al. Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic. Clin Vaccine Immunol 2014;21:1452–9
   PubMed Web of Science ®Google Scholar